|
Mylan Receives Approval for Enalapril Maleate and Hydrochlorothiazide WEDNESDAY, SEPTEMBER 19, 2001 11:51 AM - BusinessWire PITTSBURGH, Sep 19, 2001 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) today announced that it has received approval from the U.S. Food and Drug Administration for Enalapril Maleate and Hydrochlorothiazide Tablets USP, 5 mg/12.5 mg and 10 mg/25 mg the generic equivalent of Merck Research Laboratories` Vaseretic(R) Tablets. The approval follows the expiration of pediatric exclusivity granted to Merck for its Vaseretic product. Enalapril Maleate and Hydrochlorothiazide is indicated for the treatment of hypertension. It is effective alone or in combination with other antihypertensive agents. The Company is pleased to add Enalapril Maleate and Hydrochlorothiazide to its extensive portfolio of antihypertensive products. The product will be launched immediately. Current annual sales are approximately $67 million |
|
| aus der Diskussion: | generics |
| Autor (Datum des Eintrages): | dosto (19.09.01 18:13:33) |
| Beitrag: | 15 von 125 (ID:4455926) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |